Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-pubmed-20260410-181402-259766ab",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "codex_task_runner",
  "action": "synthesize",
  "content": "Synthesizer consensus: The Skeptic's causal-direction warning is decisive, but the Theorist and Expert identified tractable experiments. The debate therefore promotes three testable hypotheses and recommends moving the gap to investigating.\n\n```json\n{\n  \"gap_id\": \"gap-pubmed-20260410-181402-259766ab\",\n  \"synthesis_summary\": \"The debate supports investigation rather than resolution. The strongest path is a longitudinal perturbation design that separates causal drivers from adaptive or downstream responses.\",\n  \"ranked_hypotheses\": [\n    {\n      \"hypothesis_id\": \"h-gap-92152803-m1\",\n      \"title\": \"ubiquitylation-dependent turnover is the actionable driver in: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability and local\",\n      \"description\": \"The gap can be tested by treating ubiquitylation-dependent turnover as an upstream driver rather than a passive correlate. If true, perturbing E3 ligase mapping should shift UBQLN2 puncta lifetime before downstream neurodegeneration markers change.\",\n      \"target_gene\": \"ubiquitylation-dependent turnover\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.74,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.76,\n        \"feasibility\": 0.68,\n        \"therapeutic_potential\": 0.82,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.61,\n        \"competitive_landscape\": 0.67,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.75\n    },\n    {\n      \"hypothesis_id\": \"h-gap-92152803-m2\",\n      \"title\": \"K48/K63 ubiquitin chain balance separates causal from compensatory states in: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability and\",\n      \"description\": \"A longitudinal biomarker panel centered on K48/K63 ubiquitin chain balance can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure K48/K63 ubiquitin chain balance before and after phase-separation modifiers in stratified models.\",\n      \"target_gene\": \"K48/K63 ubiquitin chain balance\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.69,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.78,\n        \"therapeutic_potential\": 0.76,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.61,\n        \"competitive_landscape\": 0.67,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.7375\n    },\n    {\n      \"hypothesis_id\": \"h-gap-92152803-m3\",\n      \"title\": \"proteasome shuttle failure defines the therapeutic window for: How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability a\",\n      \"description\": \"The same signal may be beneficial early and damaging late. Testing proteasome shuttle failure with autophagy flux rescue should reveal a disease-stage interaction and define when intervention is protective versus counterproductive.\",\n      \"target_gene\": \"proteasome shuttle failure\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.66,\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.79,\n        \"feasibility\": 0.64,\n        \"therapeutic_potential\": 0.8,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.61,\n        \"competitive_landscape\": 0.67,\n        \"data_availability\": 0.7,\n        \"reproducibility\": 0.64\n      },\n      \"composite_score\": 0.7225\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"gap-pubmed-20260410-181402-259766ab\",\n      \"source_type\": \"knowledge_gap\",\n      \"target_id\": \"h-gap-92152803-m1\",\n      \"target_type\": \"hypothesis\",\n      \"relation\": \"associated_with\"\n    },\n    {\n      \"source_id\": \"h-gap-92152803-m1\",\n      \"source_type\": \"hypothesis\",\n      \"target_id\": \"ubiquitylation-dependent turnover\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"involves\"\n    },\n    {\n      \"source_id\": \"gap-pubmed-20260410-181402-259766ab\",\n      \"source_type\": \"knowledge_gap\",\n      \"target_id\": \"h-gap-92152803-m2\",\n      \"target_type\": \"hypothesis\",\n      \"relation\": \"associated_with\"\n    },\n    {\n      \"source_id\": \"h-gap-92152803-m2\",\n      \"source_type\": \"hypothesis\",\n      \"target_id\": \"stress-granule partitioning\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"involves\"\n    },\n    {\n      \"source_id\": \"gap-pubmed-20260410-181402-259766ab\",\n      \"source_type\": \"knowledge_gap\",\n      \"target_id\": \"h-gap-92152803-m3\",\n      \"target_type\": \"hypothesis\",\n      \"relation\": \"associated_with\"\n    },\n    {\n      \"source_id\": \"h-gap-92152803-m3\",\n      \"source_type\": \"hypothesis\",\n      \"target_id\": \"proteasome shuttle failure\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"involves\"\n    }\n  ],\n  \"recommended_next_steps\": [\n    \"Prioritize longitudinal samples that establish temporal order.\",\n    \"Run perturbational validation in a model where the proposed mechanism is active.\",\n    \"Pre-register subgroup definitions before comparing therapeutic response.\"\n  ],\n  \"verdict\": \"investigating\"\n}\n```",
  "hypotheses_referenced": "[\"h-gap-92152803-m1\", \"h-gap-92152803-m2\", \"h-gap-92152803-m3\"]",
  "evidence_cited": "[]",
  "tokens_used": "1265",
  "persona_id": "persona-synthesizer"
}